| A roadmap to using randomization in clinical trials VW Berger, LJ Bour, K Carter, JJ Chipman, CC Everett, N Heussen, ... BMC medical research methodology 21, 1-24, 2021 | 74 | 2021 |
| Adaptive clinical trial designs for phase I cancer studies O Sverdlov, WK Wong, Y Ryeznik | 35 | 2014 |
| Utility of covariate-adjusted response-adaptive randomization in survival trials O Sverdlov, WF Rosenberger, Y Ryeznik Statistics in Biopharmaceutical Research 5 (1), 38-53, 2013 | 31 | 2013 |
| An overview of healthcare data analytics with applications to the COVID-19 pandemic Z Fei, Y Ryeznik, O Sverdlov, CW Tan, WK Wong IEEE Transactions on Big Data 8 (6), 1463-1480, 2021 | 28 | 2021 |
| Implementing unequal randomization in clinical trials with heterogeneous treatment costs O Sverdlov, Y Ryeznik Statistics in Medicine 38 (16), 2905-2927, 2019 | 25 | 2019 |
| A comparative study of restricted randomization procedures for multiarm trials with equal or unequal treatment allocation ratios Y Ryeznik, O Sverdlov Statistics in Medicine 37 (21), 3056-3077, 2018 | 25 | 2018 |
| On optimal designs for clinical trials: an updated review O Sverdlov, Y Ryeznik, WK Wong Journal of Statistical Theory and Practice 14 (1), 10, 2020 | 22 | 2020 |
| Efficient and ethical response-adaptive randomization designs for multi-arm clinical trials with Weibull time-to-event outcomes O Sverdlov, Y Ryeznik, WK Wong Journal of Biopharmaceutical Statistics 24 (4), 732-754, 2014 | 19 | 2014 |
| Pharmacometrics meets statistics—A synergy for modern drug development Y Ryeznik, O Sverdlov, EM Svensson, G Montepiedra, AC Hooker, ... CPT: Pharmacometrics & Systems Pharmacology 10 (10), 1134-1149, 2021 | 17 | 2021 |
| Opportunity for efficiency in clinical development: An overview of adaptive clinical trial designs and innovative machine learning tools, with examples from the cardiovascular … O Sverdlov, Y Ryeznik, WK Wong Contemporary clinical trials 105, 106397, 2021 | 16 | 2021 |
| RARtool: A MATLAB software package for designing response-adaptive randomized clinical trials with time-to-event outcomes Y Ryeznik, O Sverdlov, WK Wong Journal of Statistical Software 66 (1), 2015 | 11 | 2015 |
| Exact Bayesian inference comparing binomial proportions, with application to proof-of-concept clinical trials O Sverdlov, Y Ryeznik, S Wu Therapeutic innovation & regulatory science 49 (1), 163-174, 2015 | 10 | 2015 |
| Doubly adaptive biased coin designs for balancing competing objectives in time-to-event trials Y Ryeznik, O Sverdlov, WK Wong Statistics and Its Interface 5 (4), 401-413, 2012 | 10 | 2012 |
| Adaptive optimal designs for dose-finding studies with time-to-event outcomes Y Ryeznik, O Sverdlov, AC Hooker The AAPS Journal 20, 1-12, 2018 | 9 | 2018 |
| Convergent Galerkin MoM solution for 2-D H-scattering from screens AG Tyzhnenko, YV Ryeznik Electromagnetics 25 (4), 329-341, 2005 | 8 | 2005 |
| Selecting a randomization method for a multi-center clinical trial with stochastic recruitment considerations O Sverdlov, Y Ryeznik, V Anisimov, OM Kuznetsova, R Knight, K Carter, ... BMC medical research methodology 24 (1), 52, 2024 | 4 | 2024 |
| Estimates of accuracy and efficiency of a MoM algorithm in for 2-D screens A Tyzhnenko, Y Ryeznik Progress In Electromagnetics Research 71, 295-316, 2007 | 4 | 2007 |
| Balancing the objectives of statistical efficiency and allocation randomness in randomized controlled trials O Sverdlov, Y Ryeznik Statistics in biopharmaceutical research 16 (4), 532-546, 2024 | 3 | 2024 |
| Imbalanced randomization (rationales for) O Sverdlov, Y Ryeznik, WK Wong Wiley StatsRef: Statistics Reference Online, 1-7, 2021 | 3* | 2021 |
| Ordinary least squares: the adequacy of linear regression solutions under multicollinearity and without it AG Tyzhnenko, YV Ryeznik | 3 | 2019 |
Oleksandr SverdlovStatistical Scientist, Novartis在 novartis.com 的电子邮件经过验证
